Novos fármacos para o tratamento da obesidade by Zanella, Maria Teresa & Ribeiro Filho, Fernando Flexa
review
C
o
p
yr
ig
h
t©
 A
BE
&
M
 to
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s.
271Arq Bras Endocrinol Metab. 2009;53/2
Emerging drugs for obesity therapy
Novos fármacos para o tratamento da obesidade
Maria Teresa Zanella1, Fernando Flexa Ribeiro Filho1
AbstrAct
Central obesity have an important impact on the development of risk factors for coronary heart disease, 
including dislipidemia, glucose intolerance, insulin resistance and hypertension. These factors contri-
bute to building cardiovascular (CV) disease as a major cause of death. The approach to obesity therapy 
should be designed to reduce CV risk and mortality. Diet and lifestyle changes remain the cornerstones 
of therapy for obesity, but the resultant weight loss is often small and long-term success is uncommon 
and disappointing. Drug therapy is considered for individuals with a body mass index greater than 
30 kg/m2 or ranging from 25 to 30 kg/m2 if they have comorbid conditions. Antiobesity agents can be 
helpful to some patients in achieving and maintaining meaningful weight loss, but yet our pharmaceu-
tical tools are of limited effectiveness considering the magnitude of the problem. At the present, only 
two drugs, orlistat and sibutramine, are approved for long-term treatment of obesity and promote no 
more than 5 to 10% of weight loss. Rimonabant, a cannabinoid-1 receptor antagonist, was withdrawn 
from the market because of concerns about its safety, including risk of suicidal and seizures, although 
very effective in promoting clinically meaningful weight loss, reduction in waist circumference, and 
improvements in several metabolic risk factors, rimonabant, a cannabinoid-1 receptor antagonist was 
withdrawn from the market because it concerns about its safety, including risk of suicidal and seizures. 
Fortunately, recent fundamental insights into the neuroendocrine mechanisms regulating body weight 
provide an expanding list of molecular targets for novel, rationally designed antiobesity drugs. In this 
review, the therapeutic potential of some antiobesity molecules in the development will be analyzed 
based on an understanding of energy homeostasis. Arq Bras Endocrinol Metab. 2009;53(2):271-280.
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resumo
Obesidade e, particularmente, a obesidade central têm influência importante na predisposição a fa-
tores de risco para doença coronariana, incluindo dislipidemia, intolerância à glicose, resistência à 
insulina e hipertensão. Tais fatores contribuem para tornar as doenças cardiovasculares (DC) causas 
frequentes de morte. Os métodos de tratamento da obesidade deveriam ser voltados à redução do 
risco e da mortalidade devido às doenças cardiovasculares. Dietas e mudanças no estilo de vida con-
tinuam sendo fatores-chave no tratamento à obesidade, mas a perda de peso resultante é geralmente 
pequena e o sucesso em longo prazo costuma ser incomum e frustrante. O tratamento com medica-
mentos é indicado para indivíduos com índice de massa corpórea superior a 30 kg/m2 ou entre 25 e 
30 kg/m2, se apresentarem comorbidades. Agentes antiobesidade podem ajudar alguns pacientes a 
alcançar e manter uma perda de peso significativa, mas, ainda assim, os agentes farmacológicos são 
pouco efetivos considerando-se a magnitude do problema. Atualmente, apenas duas drogas, orlistat 
e sibutramina, são consideradas efetivas para tratamentos em longo prazo, promovendo não mais do 
que 5% a 10% de perda de peso. Embora seja muito eficaz ao promover perda de peso significativa do 
ponto de vista clínico, redução da circunferência da cintura e melhora no perfil metabólico, o rimona-
banto, um antagonista do receptor canabinoide 1, foi retirado do mercado por fatores relacionados 
à segurança, incluindo a ocorrência de suicídios e convulsões. Felizmente, conhecimentos funda-
mentais recentes sobre mecanismos neuroendócrinos que regulam o peso corporal forneceram uma 
lista considerável de alvos moleculares para novas drogas antiobesidade produzidas racionalmente. 
Nesta revisão de literatura, a eficácia terapêutica de algumas moléculas antiobesidade será analisada 
com base no entendimento da homeostase energética. Arq Bras Endocrinol Metab. 2009;53(2):271-280.
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INtroDuctIoN 
Obesity has reached an epidemic proportion world-wide. Once considered a problem only in high-
income countries, the prevalence of obesity is now 
dramatically on the rise in low and middle-income 
countries, like Brazil. 
There is growing evidence that obesity, and particu-
larly central obesity, has an important impact on predis-
posing risk factors for coronary heart disease, includ-
ing dislipidemia, glucose intolerance, insulin resistance 
and hypertension. All these risk factors have been con-
tributing markedly to build cardiovascular disease as a 
major cause of death in the United States and many 
other countries. Thus, the approach to obesity therapy 
should be designed to reduce the risk of cardiovascular 
events and mortality.
Diet and lifestyle changes remain the cornerstones of 
therapy for obesity, but the resultant weight loss is often 
small and long-term success is extremely uncommon and 
disappointing. Drug therapy has been considered for in-
dividuals with a body mass index (BMI) greater than 
30 kg/m2, or of 25 to 30 kg/m2 if they have comorbid 
conditions. Antiobesity agents can be useful to some pa-
tients in achieving and maintaining meaningful weight 
loss, but yet our pharmaceutical tools are of limited ef-
fectiveness in the face of the magnitude of the problem. 
At present, only two drugs, orlistat and sibutramine, are 
approved for long-term use in the treatment of obesity 
and each of these typically promotes 5% to 10% of loss 
of body weigh (1,2). Although very effective in pro-
moting clinically meaningful weight loss, reduction in 
waist circumference and improvements in several meta-
bolic risk factors, rimonabant, a cannabinoid-1 recep-
tor antagonist was withdrawn from the market due to 
concerns about its safety, including risk of suicidal and 
seizures. Fortunately, recent fundamental insights into 
the neuroendocrine mechanisms regulating body weight 
provide an expanding list of molecular targets for novel, 
rationally designed antiobesity drugs. In this review, the 
therapeutic potential of some antiobesity molecules in 
the development will be analyzed based on an under-
standing of energy homeostasis.
NeuroeNDocrINe regulAtIoN of boDy 
weIght 
In most humans, body weight remains stable for long 
periods of time, despite large fluctuations in food in-
take and physical activity because energy intake and 
expenditure are matched through a neuroendocrine 
complex mechanism of energy homeostasis. The im-
portance of this control system was illustrated in a care-
ful study of 18 obese and 23 never-obese subjects who 
were monitored during caloric restriction and caloric 
excess (3). Weight loss of 10% to 20% was associated 
with a decrease in total and resting energy expenditure 
which retards further weight loss and acts coordinately 
favoring weight regain. Similarly, weight gain was as-
sociated with an increase in energy expenditure which 
retarded further weight gain. These observations reflect 
a system in which information about the status of en-
ergy reserves is transmitted to the brain by adiposity 
and satiety signals in order to modify either anabolic 
or catabolic pathways. Consequently, food intake is al-
tered in line with signaled energy requirements. This 
complex mechanism tends to maintain body weight 
and supports the theory that behavior is not the only 
determinant of obesity (4). Unfortunately, for those 
who diet, this homeostatic system defends against 
weight loss more efficiently than against weight gain. 
Body weight reduction induces decreases in circulat-
ing concentrations of leptin, nervous system tone and 
circulating thyroxine and triiodothyronine changes that 
decrease energy expenditure and acts synchronically to 
favor weight regain. Thus, understanding the mecha-
nisms that regulate energy homeostasis is essential for 
understanding novel obesity therapies in development, 
which target anabolic or catabolic regulatory networks 
to reduce food intake or increase energy expenditure to 
promote weight loss.
Energy homeostasis is maintained by adapting meal 
size to current energy requirements (Figure 1). This 
control is achieved by communication between the di-
gestive system and central nervous system (CNS). The 
status of body energy stores is communicated to the 
central nervous system by the adiposity-associated hor-
mones leptin, insulin and selected gastrointestinal (GI) 
peptides, such as ghrelin (5). Information on meal qual-
ity and content is relayed from the gastrointestinal tract 
to the brain via satiety signals which are primarily inte-
grated by the hypothalamus to determine meals size.
Acting in the brain, leptin and, in a less extent, in-
sulin decrease food intake and increase energy expen-
diture, promoting weight loss, thus being considered 
catabolic adiposity signals. Acting on the same neu-
ronal targets, ghrelin exerts the opposite effects and is 
thus termed an anabolic hormone. Weight loss evokes 
proportionate decreases in leptin and insulin and an 
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increase in ghrelin. These catabolic and anabolic sig-
nals induce corresponding alterations in catabolic and 
anabolic neuropeptides and neurotransmitters in brain 
centers responsible for energy homeostasis. 
In the central nervous system, the hypothalamus is 
one of the most important centers for energy balance, 
especially its arcuate nucleus (ARC). Leptin is primarily 
secreted from adipose tissue and its circulating levels 
are positively correlated to adiposity (6). Hypothalamic 
insulin and leptin receptors are located in ARC, on neu-
ropeptide Y (NPY) and proopiomelanocortin (POMC) 
neurons that project from the ARC to other hypotha-
lamic regions such as the paraventricular nucleus (PVN) 
and lateral hypothalamic area (LHA). Leptin and insu-
lin stimulate POMC neurons, promoting the release of 
the anorexigenic neuropeptides corticotrophin-releas-
ing hormone (CRH) and cocaine-and-amphetamine-
regulated transcript (CART) in the PVN, and inhibit-
ing the release of orexigenic neuropeptides orexin and 
melanocortin-concentrating hormone (MCH) in the 
LHA, via the release of melanocyte-stimulating hor-
mone (a-MSH) and (CART), lead to suppression of 
food intake. NPY neurons release agouti-related pro-
tein (AgRP) and gamma-aminobutyric acid (GABA); 
both tonically inhibit POMC neurons via NPY Y1 re-
ceptors. NPY/AgRP neurons inhibit the release of the 
anorexigenic neuropeptides CRH and CART in the 
PVN, promote the release of the orexigenic neuro-
peptides orexin and MCH in the LHA, via release of 
NPY, and inhibit POMC neuronal activity via release 
of AgRP and GABA, thus promoting food intake (7). 
Leptin and insulin inhibit NPY/AgRP neurons via lep-
tin and insulin receptors, thereby decreasing GABAer-
gic inhibitory input to POMC cells, which ultimately 
increases the release of CRH and CART via the PVN. 
In summary, activation of leptin receptors in ARC stim-
ulates POMC neurons and inhibits NPY neurons (6). 
When leptin levels are high after a meal, for example, 
it activates POMC neurons that suppress feeding and 
inhibits NPY neurons. As energy and leptin levels de-
crease, NPY neurons are disinhibited, thus stimula ting 
feeding and inhibiting POMC neurons. Insulin paral-
lels the actions of leptin in the ARC (8). 
The cannabinoid and serotonin (5-HT) systems, 
among other neurotransmitter systems, modulate the 
hypothalamic melanocortin and NPY feeding net-
works. It has been shown that administration of can-
nabinoid-1 receptor (CB1) agonists and antagonists 
causes hyperphagia and hypophagia, respectively (9).
These effects are mediated by modulation of the hy-
pothalamic feeding pathways. Serum endocannabinoid 
levels are elevated in obesity (10), which implies a role 
for CB1 activation in weight gain. These observations 
lead to development of rimonabant, a cannabinoid-1 
New drugs for obesity
figure 1. Signals such as leptin and insulin are secreted in proportion to the size of the fat mass and circulate in the blood. They enter the brain and act at the level of the 
hypothalamus. Neuroendocrine signals from the stomach, the gastrointestinal system and the liver are sent to the hindbrain, providing information about the food that is eaten: 
its taste and chemical content, and how much the stomach is distended.
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receptor antagonist, for the treatment of obesity. This 
agent was shown to be very effective in promoting 
weight loss and improvements in the metabolic profile 
in patients with metabolic syndrome (11). However, 
increased incidence of mood-related disorders lead to 
the withdrawn of ribonabant from the market. The de-
velopment of other cannabinoid-1 receptor antagonists 
agents for obesity therapy has been also discontinued.
Enhanced 5-HT release causes hypophagia, whereas 
inhibition of 5-HT release causes hyperphagia. These ef-
fects are mediated by 5-HT2C and 5-HT1B receptors, 
located on hypothalamic POMC and NPY neurons, 
respectively. Acting through 5-HT1B receptors, 5-HT 
hyperpolarizes and inhibits NPY/Agrp neurons, thereby 
decreasing GABAergic inhibitory input to POMC cells. 
5-HT also directly activates POMC neurons through its 
effects on 5-HT2C receptors. These processes lead to 
a reciprocal increase in a-MSH and decrease in AgRP 
release at melanocortin target sites (12).
In addition to digesting and assimilating nutrients, 
the gastrointestinal system play a key-role sensing and 
signaling the physiology of energy homeostasis. The 
gut, the pancreatic islets of Langerhans, and elements 
in the portal vasculature, communicate with the con-
trollers of energy balance in the brain by means of neu-
ral and endocrine pathways. Short-term alterations in 
nutrient status are communicated to the brain through 
satiety signals from the gastrointestinal (GI) tract. In 
response to volumetric and caloric cues, GI peptides 
(as cholecystokinin, peptide YY3-36, pancreatic poly-
peptide and glucagon-like peptide-1) are released in 
the gut during feeding (13) and, binding to specific 
receptors on the vagus nerve, convey information to 
the brain. These satiety signals, and those from the hy-
pothalamic feeding networks, are integrated centrally 
to determine meal size. Amylin, which is a peptide co-
secreted with insulin from the pancreas in response to 
meals, also promotes satiety (14). The sensitivity of the 
brain response to afferent GI satiation signals is en-
hanced by long-acting catabolic adiposity hormones, 
leptin and insulin, which also contribute to regulat-
ing meal size (5). In the opposite way, secretion of the 
orexigenic peptide ghrelin, primarily from the stomach, 
occurs shortly before, rather than after, meals, and by 
increasing hunger it appears to promote meal initia-
tion. Ghrelin also increases with weight loss and, act-
ing on the hypothalamus, hindbrain, vagus nerve, and 
mesolimbic reward centers, promote increases in food 
intake and body weight.
eXPerImeNtAl Drugs 
Considering the lack of successful weight-loss treat-
ments and the public-health implications of the obesity 
pandemic state, the development of safe and effective 
drugs should be a priority. There are several pharma-
cological agents in development that results in weight 
loss, either by a reduction in food intake, or by increas-
ing energy expenditure. 
central stimulators agents of catabolic pathways 
leptin 
Leptin is a peptide produced primarily in adipose tis-
sue. In mice and in few humans with leptin deficiency, 
the administration of physiological doses of leptin de-
creases food intake and causes weight loss (15). When 
first identified, it was hoped that leptin would provide 
an effective antiobesity therapy. However, shortly it was 
discovered that obese patients are leptin-resistant and 
have elevated circulating leptin levels, which can be re-
duced with weight loss. In a study with 47 obese wom-
en and men given placebo or varying doses of recombi-
nant human leptin for 24 weeks (and advised to eat 500 
kcal less than requirement each day), there was a weakly 
dose-dependent decrease in body weight, ranging from 
-1.3 kg in the placebo group to -1.4 kg in the 0.03 
mg/kg group and to -7.1 kg in the 0.30 mg/kg group 
(16). These results suggest that leptin resistance can be 
overcome with high doses of leptin, but it is not known 
whether the effect can be sustained or not. One small 
study suggested that leptin therapy may prevent regain-
ing weight after significant weight loss by preventing 
the weight gain associated to the decrease in energy 
expenditure (15). Thus, leptin could be developed as 
an adjunctive therapy to a primary weight loss agent to 
reduce the counter-regulatory neuroendocrine effects 
of low leptin levels. 
Mechanisms of insulin and leptin resistance
The intracellular signaling mechanisms involved in 
hypothalamic leptin and insulin resistance are under ac-
tive investigation. Experimental studies in animals with 
diet-induced obesity have identified some potential me-
diators of leptin resistance in brain areas critical to ener-
gy homeostasis. Leptin receptor activation engages two 
intracellular proteins that terminate receptor signaling – 
namely, suppressor of cytokine signaling-3 (SOCS3) and 
protein tyrosine phosphatase-1B (PTP1B) – and inhibi-
tion of either of these autoinhibitory factors could theo-
New drugs for obesity
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retically increase leptin sensitivity (17,18). It has been 
shown that SOCS3 activity is increased in obesity, which 
suggests an etiological role in leptin resistance. How-
ever, the inhibition of SOCS3 as a strategy to treat obe-
sity deserves caution since SOCS3 regulates more than 
just leptin signaling, and homozygous global knockout 
mice die in utero (19). Also, potentially, PTB1B might 
be a viable antiobesity drug target, since PTP1B knock-
out mice are hypersensitive to insulin and leptin and 
resistant to obesity when fed a high-fat diet (20). In 
addition, it has been shown that selective blockade of 
PTP1B expression, induced by infusion of an antisense 
oligonucleotide, in rat hypothalamic areas surrounding 
the third ventricle, results in decreases in food intake, 
reductions in body weight and adiposity after high-fat 
diet. These effects were associated with increases in lep-
tin and insulin action in hypothalamus (21). However, 
translating these promising findings into clinical utility 
is related to the difficulty of inhibiting PTP1B selective-
ly in body-weight regulatory circuits without interfer-
ing in other important functions of this enzyme.
It is well known that obesity is associated with a 
state of abnormal inflammatory response. The Toll-like 
receptor 4 (TLR4) is a subclass of Toll-like receptors 
which play an important role in inflammation and im-
munity. TLR4 can be activated by saturated fatty acids 
(22) and has been recognized as a mediator in the cross-
talk between inflammatory and metabolic signals. The 
activation of TLR4 signaling leads to up regulation of in-
tracellular inflammatory pathways that induce insulin re-
sistance (23). Furthermore, mice with a loss-of-function 
mutation in TLR4 are protected against the develop-
ment of diet-induced obesity and insulin resistance (24). 
More recently it was shown that in animal models of 
diet-induced obesity, TLR4 acts as a predominant mo-
lecular target for saturated fatty acids in the hypothala-
mus and, triggering the intracellular signaling network, 
induces an inflammatory response which determines the 
resistance to the anorexigenic hormones insulin and lep-
tin (25). Thus, a selective interference with TLR4 or 
even with the inflammatory response to its activation 
may emerge, in the future, as an important strategy for 
the treatment of obesity and insulin resistance.
melanocortin-4 receptor agonists
In the leptin-melanocortin pathway, POMC is the 
first key intermediary downstream of leptin-receptor 
signaling. By enhancing energy expenditure and sup-
pressing appetite, melanocortin peptides derived from 
POMC play a primary role in the hypothalamic regula-
tion of body weight. Cleavage of POMC by prohor-
mone convertase-1 produces, among other peptides, 
a-MSH, which activates melanocortin-3 and -4 recep-
tors (MC3R, MC4R). These receptors were recognized 
as possible targets for antiobesity therapies because of 
their specific roles in energy homeostasis and their posi-
tion downstream the locus of leptin resistance.
 In a study in normal-weight adults, the 6-week 
intranasal administration of the MSH/ACTH (4-10) 
core fragment of POMC resulted in a distinct reduction 
of body weight and body fat, accompanied by signifi-
cant decreases in leptin and insulin plasma concentra-
tions (26). However, in overweight individuals, MSH/
ACTH (4-10) did not induce any significant reduction 
in body weight, body fat, and plasma levels of insulin 
and leptin as compared to the effects of placebo. The 
authors conclude that, contrasting with normal-weight 
humans, overweight subjects are not susceptible to the 
effects of melanocortin administration on hypothalam-
ic weight regulatory systems. The hypothesis is that in 
overweight subjects, a decreased sensitivity to ACTH/
MSH peptides may derive from alterations at the level 
of the melanocortin receptors or at subsequent steps in 
the processing of the body fat signal (27).
subtype-selective serotonin-receptor agonists
Three of the pharmacological agents that have been used 
clinically to treat obesity – sibutramine, fenfluramine, 
and dexfenfluramine (d-FEN) – all increase signaling by 
the neurotransmitter serotonin [5-hydroxytryptamine 
(5-HT)]. Anorectic medications targeting the 5-HT 
system are typically derived from b-phenethylamine (the 
skeletal structure of the neurotransmitters dopamine, 
noradrenalin and adrenaline), and mediate their effects 
by influencing noradrenergic, dopaminergic and sero-
tonergic neurotransmission. Increasing the availability 
of 5-HT by affecting its release and reuptake in the 
synaptic cleft, or the direct activation of the 5-HT re-
ceptors, reduces food consumption, whereas decreasing 
5-HT receptor activation produces the opposite effect. 
Serotonin is a monoaminergic neurotransmitter that 
acts through a family of at least fourteen 5-HT recep-
tor subtypes to modulate numerous sensory, motor, and 
behavioral processes. Serotonin 5-HT1B and 5-HT2C 
receptors have been specifically recognized as mediators 
of serotonin-induced satiety, probably acting through 
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the hypothalamic melanocortin system. Acting through 
5-HT1B receptors, 5-HT hyperpolarizes and inhibits 
NPY/AGRP neurons, thus decreasing GABAergic in-
hibitory input to POMC cells. Serotoninergic agents also 
activate hypothalamic POMC neurons through 5-HT2C 
receptors which subsequently activates MC3R and MC4R, 
reducing food intake (28). Sibutramine, dexfenfluramine, 
fluoxetine and the 5-HT2C receptor agonist chlorophe-
nylpiperazine (mCPP) have showed to modify appetite 
in both lean and obese humans, resulting in reduced ca-
loric intake. In addition to its serotoninergic action, it 
has been shown in lipopolysaccharide (LPS)-stimulated 
microglia and astrocyte cultures that mCPP attenuates 
the expression of pro-inflammatory cytokines, such as IL-
1beta and TNF-alpha, and inhibits both the activation of 
the nuclear factor-kappa B and phosphorylation of p38 
mitogen-activated protein kinase (29). Considering that 
the activation of TLR4 by saturated fatty acids is impli-
cated in the up regulation of intracellular inflammatory 
pathways involved in the hypothalamic leptin and insulin 
resistance (27), this cerebral anti-inflammatory action of 
mCPP, theoretically, can contribute to the anorexigenic 
action of this compound. However, this potential drug 
mechanism of action has to be proven yet. 
Several 5-HT2C receptor agonists are in develop-
ment. Lorcaserin (APD356) is a selective 5-HT2C recep-
tor agonist for obesity, which is currently undergoing 
the final phase III of clinical trials. Phase IIb data for this 
compound demonstrated average weight loss of 1.8, 2.6 
and 3.6 kg following a 12-week administration of 10, 
15 or 20 mg daily, respectively, compared with 0.3 kg 
for the placebo group (30). Lorcaserin does not cause 
heart valve damage in the same way as previously with-
drawn serotonergic drugs. After 12 months of obser-
vation, the echocardiograms of the participants of the 
first of three Phase III clinical trials (“BLOOM”) did 
not meet the trial-stopping criteria developed by an in-
dependent Echocardiographic Data Safety Monitoring 
Board (EDSMB), and so the trial continues (31). Also in 
development is the 5-HT2C agonist WAY-163909 (32).
ceNtrAl INhIbItors AgeNts of ANAbolIc 
PAthwAys
Neuropeptide y (NPy) 
NPY is a hypothalamic anabolic neuropeptide inhibited 
by the anorexigenic hormones insulin and leptin. It has 
been shown that chronic NPY administration powerfully 
increases food intake and body weight. NPY, however, is 
the most abundant central neuropeptide, with pleiotro-
pic functions that act through at least five receptors sub-
types (Y1, Y2, Y4, Y5, and Y6). It imposes a difficulty 
to target them for obesity without eliciting unacceptable 
side effects. Some studies identified the Y5 receptor as 
one of the isoforms responsible for the orexigenic effects 
of NPY that could be targeted to promote weight loss. 
The NPY Y5 receptor is located on POMC neurons in 
the ARC and preclinical data have shown marked hyper-
phagia on administration of selective Y5 receptor ago-
nists. Compounds targeting the NPY system, S-2367 
and MK-0577, are NPY Y5 receptor antagonists. How-
ever, in a clinical trial with obese patients, administered 
S-2367 (1,600 mg, 12 weeks) promoted a weight loss 
of 3.6 kg. However in a 1-year phase, two trials of MK-
0577 were abandoned because of lack of efficacy (33). 
melanin-concentrating hormone (mch) 
Another leptin-inhibited orexigenic hypothalamic neu-
ropeptide is melanin-concentrating hormone (MCH). 
This peptide acts downstream of at least some levels of 
leptin resistance and is expressed in neurons of the lat-
eral hypothalamic area. The feeding effects of MCH are 
mediated by, the MCH1 receptor (MCHR1) (34). Me-
dicinal blockade of MCH signaling has been explored as 
an antiobesity modality. However, MCH regulates many 
functions beyond feeding, such as locomotor activity, 
anxiety, aggression, sensory processing and learning; it 
is not easy to design anti-MCH agents that selectively 
modulate energy homeostasis without eliciting unde-
sirable side effects. MCHR1 antagonism has yet to be 
proven as an effective treatment for obesity.
gAstroINtestINAl PePtIDes thAt regulAte 
fooD INtAKe 
Many of the circulating gastrointestinal peptides have 
direct access to regions of the brain involved in the reg-
ulation of food intake, including the arcuate nucleus 
(ARC) of the hypothalamus and the area postrema. 
These peptides may also function outside of the CNS 
to influence the activity of neurons such as the vagal 
nerve, which projects to the nucleus of the solitary tract 
(NTS) in the brain stem (Figure 1).
Peptide yy (Pyy) 
The gut hormone peptide YY (PYY) suppresses appe-
tite and decreases food intake apparently by activating 
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autoinhibitory receptors on orexigenic NPY/AGRP 
neurons in the hypothalamus, and thereby derepressing 
anorexigenic POMC neurons. It has been shown, in a 
trial of obese and lean adults, that short-term intrave-
nous PYY3-36 administration decreased appetite and ca-
loric intake by approximately 30% in both groups, sug-
gesting that PYY might be a useful therapy for weight 
loss (35). Also, the observation that the anorectic effi-
cacy of exogenous PYY3-36 is
 fully intact in obese people, 
encouraged long-term studies to determine whether 
chronic administration of PYY3-36
 or related peptidomi-
metics could promote weight loss. However, in a 12-
week trial of 133 obese patients who were randomly 
assigned to intranasal PYY (200 or 600 mcg three times 
a day before meals) or placebo, in conjunction with diet 
and exercise, weight loss was similar in the placebo and 
200 mcg PYY groups (2.8 and 3.7 kg, respectively) 
(36). Weight loss could not be assessed in the 600 mcg 
PYY group, because 60% of patients dropped out due 
to nausea and vomiting.
Pancreatic polypeptide (PP)
A 36-amino-acid peptide that is primarily expressed in 
the duodenal endocrine cells of the pancreas and distal 
gut belongs to the same peptide family as PYY. Plasma 
PP concentrations are primarily regulated by food in-
take. Like PYY(3–36) PP is released postprandially, but in 
a biphasic manner, in proportion to calories ingested. In 
normal-weight individuals, PP infusion rapidly dimin-
ishes appetite after just two hours, and causes a pro-
longed decrease in food intake over the following 24 
hours (37). As with PYY(3–36), levels of PP are lower in 
obese subjects. Circulating PP is thought to mediate its 
anorectic effects through the highly expressed Y4 recep-
tors located in the area postrema. A synthetic analogue 
(TM30338) of both PYY(3–36) and PP, which acts as an 
agonist of both the Y2 and Y4 receptors, is under develo-
pment. Recently, reported data indicate that once-a-day 
subcutaneous dosing of TM30338 in obese human sub-
jects inhibited food intake, at a statistically significant 
level, up to at least nine hours after dosing (38).
glucagon-like peptide-1 (glP-1) 
Exendin-4 (39) exenatide (Byetta; Amylin/Lilly), is a 
naturally occurring agonist of the GLP-1 receptor iso-
lated from the lizard Heloderma suspectum and has 
longer biological activity than GLP-1. This protease-re-
sistant GLP-1 congener increases insulin secretion and 
possibly sensitivity, being already marketed to treat dia-
betes. In clinical trials, beyond reductions in hemoglo-
bin A1C, exenatide promotes a modest but progressive 
weight loss (40) which is especially remarkable because 
improvements in glycemic control achieved with other 
agents typically promote weight gain. The mechanisms 
mediating anorectic effects of GLP-1 are not fully 
known but they appear to play an important role for 
the vagus nerve. Other GLP-1 analogue, liraglutide, is 
also reported to produce weight loss and reduce food 
intake. Although GLP-1 receptor agonists are not cur-
rently approved for obesity treatment, the impressive 
effects of exenatide on body weight demands consider-
ation of such agents for this indication. 
oxyntomodulin 
Oxyntomodulin is a peptide produced in L-cells of the 
GI tract from the proglucagon gene product. Chronic 
oxyntomodulin injections in animals decrease body 
weight more than expected from the reduction in food 
intake, suggesting an additional effect of increasing en-
ergy expenditure. When self-administered three times 
a day 30 minutes before meals in obese volunteers the 
group (n = 14) treated with oxyntomodulin lost 2.3 ± 
0.4 kg, compared to 0.5 ± 0.5 kg in those treated with 
placebo. Food intake was reduced by 250 kcal (35% ± 
9%) in the last meal (41).This modest but favorable re-
sults provide justification for larger, longer term trials of 
oxyntomodulin as a potential antiobesity agent.
Amylin 
Amylin, a 37-amino acid peptide that is stored in pan-
creatic b-cells and is co-secreted with insulin postpran-
dially from pancreatic b-cells, inhibits gastric emptying, 
gastric acid output, and glucagon secretion. It can also 
dose-dependently decrease meal size and food intake 
through vagus-independent actions on the hindbrain 
area postrema. Pramlintide is a stable, soluble, nonag-
gregating, equipotent amylin analog that is adminis-
tered by mealtime subcutaneous injection. It is mar-
keted for diabetes treatment, but it also causes mild 
progressive weight loss for at least 16 week in humans 
(42). Pramlintide does not cause hypoglycemia in the 
absence of therapies with other hypoglycemic agents, 
since its effects are glucose-dependent and are overrid-
den as serum glucose levels fall. It has been shown that 
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supraphysiologic doses of pramlintide do not provoke 
hypoglycemia in normal subjects. 
The effects of pramlintide were assessed in non dia-
betic obese patients. In a randomized, double-blind, 
placebo-controlled study, 204 obese subjects self-ad-
ministered pramlintide (nonforced dose escalation < or 
= 240 mg) or placebo via subcutaneous injection three 
times a day before meals for 16 week, without concom-
itant lifestyle intervention (43). The drug was generally 
well tolerated, and the withdrawal rates were similar to 
placebo (25%) and pramlintide-treated groups (29%). 
Subjects completing 16 week of pramlintide treatment 
experienced placebo-corrected reductions in body 
weight of 3.7% ± 0.5% and in waist circumference of 
3.6 ± 1.1 cm; approximately 31% of subjects treated 
with pramlintide achieved 5% or greater weight loss 
compared to 2% in the placebo group. These results 
support continued evaluation of pramlintide as a poten-
tial treatment for obesity. 
AgeNts ActINg through PerIPherAl 
mechANIsms 
lipase inhibitors 
Lipase inhibitors inhibit gastric and pancreatic lipases in 
the lumen of the gastrointestinal tract to decrease sys-
temic absorption of dietary fat. Krista (Xenia; Roche), 
or tetra-hydrolipstatin, is indicated for the management 
of obesity (including weight loss and weight mainte-
nance) when used in conjunction with a diet of reduced 
calories. The only other lipase inhibitor currently in 
clinical development for the treatment of obesity is 
ATL-962 (Cetilistat; Alizyme). Clinical data available 
indicate that ATL-962 has comparable efficacy to or-
listat (Phase IIb clinical trial showed 3 kg weight loss 
over placebo in three months) but with a favorable side-
effect profile (90% fewer severe gastrointestinal side ef-
fects) compared with that reported for orlistat. 
lipid metabolism modulators 
Human growth hormone (hGH) has lipolytic/antilipo-
genic properties. As an inhibitor of lipoprotein lipase, it 
can increase circulation of free fatty acids and ultimately 
reduce fat-cell mass (44). Levels of human growth hor-
mone are typically suppressed in the obese state and with 
increasing age. It has been shown that hGH therapy re-
duces abdominal fat both in men and postmenopausal 
women (45,46). However, clinical applications of hGH 
for long-term obesity treatment have not been success-
ful because of its diabetogenic and other unwanted side 
effects. The lipolytic domain of the hGH molecule has 
been identified as the carboxyl terminus of the intact 
hormone (residues 177-191). hGH(177–191) inhibits the 
activity of acetyl co-enzyme A carboxylase in adipocytes 
and hepatocytes, which reduces glucose incorporation 
into lipid in both isolated cells and tissues, and there-
by enhances the breakdown of stored fats, and inhib-
its the synthesis of new fat (47) without the diabeto-
genic effects associated with the amino-terminal region 
of the molecule. The fragment hGH(177–191) is currently 
under development by Metabolic Pharmaceuticals as 
AOD9604, an orally available peptide (due to cycliza-
tion) described as a lipid-metabolism modulator. Results 
of a Phase IIb clinical trial showed that administration of 
1 mg AOD9604 once a day led to weight loss of 2.0 kg 
more than placebo over the course of 12 weeks.
Compounds that aim at reducing body weight by in-
creasing energy expenditure have also been explored. b3-
adrenergic receptor agonists cause lipolysis and increase 
thermogenesis. However, several phase 2 trials with b3-
adrenergic receptor agents have been discontinued be-
cause of poor drug efficacy and safety profiles (48).
Thyroid hormone increases thermogenesis via thyroid 
hormone receptor b subtype. Thyroid hormone receptor 
agonists have been investigated as potential therapeutic 
targets, but with limited success, as it was proved the 
difficulty in developing selective compounds with good 
safety profiles. 
combINAtIoN therAPIes
Body weight is defended by redundant regulatory sys-
tems so that weight loss resulting from an intervention 
that only stimulates metabolic rate should elicit an adap-
tive increase in food intake. On the other hand, pharma-
cological antagonism of anabolic signals is theoretically 
limited in its ability to promote major weight reduction 
because changes in other pathways could compensate for 
the loss of an orexigen mechanism. Therefore, as in other 
chronic diseases (e.g., hypertension, diabetes), combina-
tion therapies targeting several points in the network may 
be necessary to achieve effective control of body weight. 
Qnexa (VI-0521), a pharmaceutical combination 
containing low doses of the amphetamine-derived 
compound and a catecholamine releaser, phentermine 
with and the anticonvulsant agent topiramate, is being 
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developed for obesity. Topiramate is a sulphamate-sub-
stituted fructose that is approved as an anti-epileptic/
antimigraine agent and which has multifactorial effects 
on the CNS, involving blockade of voltage-dependent 
sodium channels and action on the GABA (g-amino bu-
tyric acid) and glutamate systems (49). Phase II data for 
Qnexa demonstrated a placebo-adjusted non-plateaued 
weight loss of 9.2 kg after 24 weeks, and the propor-
tion of patients achieving 10% or more total body 
weight loss was greater than the sum of phentermine 
and topiramate comparator agents administered alone. 
Subjects with an average BMI of 38 received daily dos-
es of Qnexa (or placebo/one of the active ingredients 
separately), and were asked to reduce caloric intake by 
500 calories per day.  
Contrave, a combination of the centrally acting 
medications bupropion, a dopamine and noradrenalin-
reuptake inhibitor that has demonstrated dose-related 
weight loss (50), and naltrexone, an opioid-receptor an-
tagonist used to treat narcotic and alcohol dependency. 
Bupropion and naltrexone have been reported to syner-
gistically stimulate the pro-opiomelanocortin (POMC) 
system that is associated with reducing food intake by 
blocking a b-endorphin-mediated inhibition of POMC 
neurons. Phase II data for Contrave (bupropion 150 mg 
b.i.d., naltrexone 50 mg q.d., 24 weeks) demonstrated 
a 6.6% non-plateaued weight loss after 24 weeks in sub-
jects with a BMI ranging from 30 to 40, in comparison 
with 3.8% (bupropion alone), 2.2% (naltrexone alone) 
and 0.9% (placebo), respectively (51). Although nausea 
(40%) led to withdrawals, it is thought that dosage ad-
justment of the components might diminish it.
Excalia is a combination of bupropion and zonis-
amide, an anticonvulsant; both enhance the release of 
a-MSH and CART and increase 5-HT levels. In a short-
term, open-label, preliminary trial, combination treat-
ment of zonisamide and bupropion resulted in more 
weight loss than treatment with zonisamide alone (52). 
Finally, combination therapy with sibutramine and lep-
tin has been shown, in preclinical studies, to cause a 
synergistic decrease in body weight (53).
coNclusIoNs 
Despite the incredible gains in our understanding of energy 
homeostasis, much remains unknown regarding the com-
plex central and peripheral mechanisms that underlie obe-
sity. Like many drugs for chronic disease, medication is not 
a cure, but an indutor of a pharmacologic effect that occurs 
while it is taken. Moving forward, treatment with a com-
bination of agents may result in better outcomes in obesity 
therapy while more efficacious drugs are not available.
Disclosure: No potential conflict of interest relevant to this article 
was reported. 
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